• Consensus Rating: Buy
  • Consensus Price Target: $69.00
  • Forecasted Upside: 227.64 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$21.06
▼ -2.08 (-8.99%)

This chart shows the closing price for XOMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New XOMA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XOMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XOMA

Analyst Price Target is $69.00
▲ +227.64% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for XOMA in the last 3 months. The average price target is $69.00, with a high forecast of $69.00 and a low forecast of $69.00. The average price target represents a 227.64% upside from the last price of $21.06.

This chart shows the closing price for XOMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in XOMA. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/10/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/10/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2022HC WainwrightReiterated RatingBuy$69.00Low
10/8/2021HC WainwrightBoost TargetBuy$56.00 ➝ $69.00High
9/9/2021AegisLower TargetBuy$60.00 ➝ $56.00Low
9/7/2021WedbushDowngradeOutperform ➝ Neutral$22.00High
6/29/2021AegisInitiated CoverageBuy$60.00High
1/19/2021HC WainwrightBoost TargetBuy$30.00 ➝ $56.00High
11/25/2020WedbushReiterated RatingBuy$36.00Low
8/25/2020WedbushReiterated RatingOutperformHigh
5/5/2020WedbushReiterated RatingBuy$29.00Low
5/5/2020HC WainwrightReiterated RatingBuy$30.00Low
3/23/2020WedbushReiterated RatingBuy$29.00High
3/9/2020HC WainwrightReiterated RatingBuy$30.00High
12/6/2019HC WainwrightReiterated RatingBuy$30.00Low
9/27/2019HC WainwrightSet TargetBuy$30.00Medium
8/7/2019WedbushReiterated RatingBuy$25.00Medium
8/1/2019WedbushReiterated RatingBuy$25.00Medium
6/14/2019HC WainwrightSet TargetBuy$30.00Medium
5/14/2019WedbushSet TargetBuy$25.00High
4/12/2019HC WainwrightSet TargetBuy$30.00Medium
3/11/2019WedbushReiterated RatingBuy$26.00High
11/8/2018CowenReiterated RatingHoldHigh
11/7/2018HC WainwrightSet TargetBuy$36.00High
10/19/2018HC WainwrightSet TargetBuy$36.00High
9/21/2018HC WainwrightReiterated RatingBuy$49.00Medium
9/17/2018WedbushReiterated RatingOutperformHigh
8/14/2018S&P Equity ResearchLower Target$18.74 ➝ $16.26Medium
8/8/2018WedbushReiterated RatingOutperform$33.00High
5/10/2018CowenReiterated RatingHoldHigh
5/10/2018HC WainwrightSet TargetBuy$49.00High
4/30/2018HC WainwrightSet TargetBuy$49.00High
3/9/2018HC WainwrightSet TargetBuy$49.00High
1/18/2018HC WainwrightReiterated RatingBuy ➝ Buy$49.00Medium
12/19/2017WedbushReiterated RatingBuy$33.00Low
12/7/2017HC WainwrightSet TargetBuy$38.00Medium
(Data available from 12/5/2017 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
5/9/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/8/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/8/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/7/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/6/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/5/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
XOMA logo
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $21.06
Low: $20.56
High: $22.50

50 Day Range

MA: $18.17
Low: $16.00
High: $25.45

52 Week Range

Now: $21.06
Low: $15.68
High: $32.08

Volume

21,900 shs

Average Volume

35,168 shs

Market Capitalization

$241.16 million

P/E Ratio

61.94

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of XOMA?

The following sell-side analysts have issued reports on XOMA in the last twelve months: HC Wainwright, StockNews.com, and TheStreet.
View the latest analyst ratings for XOMA.

What is the current price target for XOMA?

1 Wall Street analysts have set twelve-month price targets for XOMA in the last year. Their average twelve-month price target is $69.00, suggesting a possible upside of 227.6%. HC Wainwright has the highest price target set, predicting XOMA will reach $69.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $69.00 for XOMA in the next year.
View the latest price targets for XOMA.

What is the current consensus analyst rating for XOMA?

XOMA currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XOMA will outperform the market and that investors should add to their positions of XOMA.
View the latest ratings for XOMA.

What other companies compete with XOMA?

How do I contact XOMA's investor relations team?

XOMA's physical mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company's listed phone number is (510) 204-7200 and its investor relations email address is [email protected] The official website for XOMA is www.xoma.com. Learn More about contacing XOMA investor relations.